These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 30137336)

  • 21. New Aspects of the Virus Life Cycle and Clinical Utility of Next Generation Sequencing based HIV-1 Resistance Testing in the Genomic, the Proviral, and the Viral Reservoir of Peripheral Blood Mononuclear Cells.
    Pröll J; Paar C; Taylor N; Skocic M; Freystetter A; Blaimschein A; Mayr R; Niklas N; Atzmüller S; Raml E; Wechselberger C
    Curr HIV Res; 2022; 20(3):213-221. PubMed ID: 35331114
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Low Incidence of HIV-1C Acquired Drug Resistance 10 Years after Roll-Out of Antiretroviral Therapy in Ethiopia: A Prospective Cohort Study.
    Mulu A; Maier M; Liebert UG
    PLoS One; 2015; 10(10):e0141318. PubMed ID: 26512902
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Low rate of genotypic HIV-1 drug-resistant strains in the Senegalese government initiative of access to antiretroviral therapy.
    Vergne L; Kane CT; Laurent C; Diakhaté N; Gueye NF; Gueye PM; Sow PS; Faye MA; Liégeois F; Ndir A; Lanièce I; Peeters M; Ndoye I; Mboup S; Delaporte E
    AIDS; 2003 Jul; 17 Suppl 3():S31-8. PubMed ID: 14565607
    [TBL] [Abstract][Full Text] [Related]  

  • 24. HIV drug resistance mutations in proviral DNA from a community treatment program.
    Derache A; Shin HS; Balamane M; White E; Israelski D; Klausner JD; Freeman AH; Katzenstein D
    PLoS One; 2015; 10(1):e0117430. PubMed ID: 25635815
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Emergence of protease inhibitor resistance-associated mutations in plasma HIV-1 precedes that in proviruses of peripheral blood mononuclear cells by more than a year.
    Bi X; Gatanaga H; Ida S; Tsuchiya K; Matsuoka-Aizawa S; Kimura S; Oka S
    J Acquir Immune Defic Syndr; 2003 Sep; 34(1):1-6. PubMed ID: 14501787
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ultradeep sequencing of B and non-B HIV-1 subtypes: Viral diversity and drug resistance mutations before and after one month of antiretroviral therapy in naive patients.
    Epaulard O; Signori-Schmuck A; Larrat S; Kulkarni O; Blum MG; Fusillier K; Blanc M; Leclercq P; François O; Morand P
    J Clin Virol; 2017 Oct; 95():13-19. PubMed ID: 28830014
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Both human immunodeficiency virus cellular DNA sequencing and plasma RNA sequencing are useful for detection of drug resistance mutations in blood samples from antiretroviral-drug-naive patients.
    Parisi SG; Boldrin C; Cruciani M; Nicolini G; Cerbaro I; Manfrin V; Dal Bello F; Franchin E; Franzetti M; Rossi MC; Cattelan AM; Romano L; Zazzi M; Andreoni M; Palù G
    J Clin Microbiol; 2007 Jun; 45(6):1783-8. PubMed ID: 17442799
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Insights about minority HIV-1 strains in transmitted drug resistance mutation dynamics and disease progression.
    Leda AR; Hunter J; Oliveira UC; Azevedo IJ; Sucupira MCA; Diaz RS
    J Antimicrob Chemother; 2018 Jul; 73(7):1930-1934. PubMed ID: 29684141
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pretreatment HIV drug resistance among adults initiating ART in Namibia.
    Taffa N; Roscoe C; Sawadogo S; De Klerk M; Baughman AL; Wolkon A; Mutenda N; DeVos J; Zheng DP; Wagar N; Prybylski D; Yang C; Hamunime N; Agolory S; Raizes E
    J Antimicrob Chemother; 2018 Nov; 73(11):3137-3142. PubMed ID: 30137412
    [TBL] [Abstract][Full Text] [Related]  

  • 30. High concordance between HIV-1 drug resistance genotypes generated from plasma and dried blood spots in antiretroviral-experienced patients.
    Masciotra S; Garrido C; Youngpairoj AS; McNulty A; Zahonero N; Corral A; Heneine W; de Mendoza C; García-Lerma JG
    AIDS; 2007 Nov; 21(18):2503-11. PubMed ID: 18025887
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The mutational archive in proviral DNA does not change during 24 months of continuous or intermittent highly active antiretroviral therapy.
    Palmisano L; Giuliano M; Galluzzo CM; Amici R; Andreotti M; Weimer LE; Pirillo MF; Fragola V; Bucciardini R; Vella S
    HIV Med; 2009 Sep; 10(8):477-81. PubMed ID: 19459989
    [TBL] [Abstract][Full Text] [Related]  

  • 32. High level of HIV-1 resistance in patients failing long-term first-line antiretroviral therapy in Mali.
    Fofana DB; Soulié C; Baldé A; Lambert-Niclot S; Sylla M; Ait-Arkoub Z; Diallo F; Sangaré B; Cissé M; Maïga IA; Fourati S; Koita O; Calvez V; Marcelin AG; Maïga AI
    J Antimicrob Chemother; 2014 Sep; 69(9):2531-5. PubMed ID: 24855120
    [TBL] [Abstract][Full Text] [Related]  

  • 33. HIV-1 proviral resistance mutations: usefulness in clinical practice.
    Kabamba-Mukadi B; Duquenne A; Henrivaux P; Musuamba F; Ruelle J; Yombi JC; Bodéus M; Vandercam B; Goubau P
    HIV Med; 2010 Sep; 11(8):483-92. PubMed ID: 20163482
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Decay of HIV type 1 DNA and development of drug-resistant mutants in patients with primary HIV type 1 infection receiving highly active antiretroviral therapy.
    Riva E; Pistello M; Narciso P; D'Offizi G; Isola P; Galati V; Turriziani O; Tozzi V; Vincenzi L; Dianzani F; Antonelli G
    AIDS Res Hum Retroviruses; 2001 Nov; 17(17):1599-604. PubMed ID: 11779347
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Persistence of HIV-1 transcription in peripheral-blood mononuclear cells in patients receiving potent antiretroviral therapy.
    Furtado MR; Callaway DS; Phair JP; Kunstman KJ; Stanton JL; Macken CA; Perelson AS; Wolinsky SM
    N Engl J Med; 1999 May; 340(21):1614-22. PubMed ID: 10341273
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Long-Range HIV Genotyping Using Viral RNA and Proviral DNA for Analysis of HIV Drug Resistance and HIV Clustering.
    Novitsky V; Zahralban-Steele M; McLane MF; Moyo S; van Widenfelt E; Gaseitsiwe S; Makhema J; Essex M
    J Clin Microbiol; 2015 Aug; 53(8):2581-92. PubMed ID: 26041893
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cellular HIV-1 DNA quantification and short-term and long-term response to antiretroviral therapy.
    Masquelier B; Taieb A; Reigadas S; Marchou B; Cheneau C; Spire B; Charpentier C; Leport C; Raffi F; Chêne G; Descamps D;
    J Antimicrob Chemother; 2011 Jul; 66(7):1582-9. PubMed ID: 21525020
    [TBL] [Abstract][Full Text] [Related]  

  • 38. HIV-1 genotype after interruption of non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy and virological response after resumption of the same regimen.
    Sungkanuparph S; Kiertiburanakul S; Apisarnthanarak A; Malathum K; Sathapatayavongs B
    Int J STD AIDS; 2007 Dec; 18(12):832-4. PubMed ID: 18073016
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Persistence of HIV-1 drug resistance mutations and emergence during antiretroviral treatment interruption: considerations from a clinical case.
    Torti C; Moretti F; Uccelli MC; Tirelli V; Quiros-Roldan E; Gargiulo F; Carosi G
    Med Sci Monit; 2003 Apr; 9(4):CS16-9. PubMed ID: 12709675
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The relevance of ultradeep sequencing for low HIV-1 viral loads and proviruses in the clinical setting.
    Foury A; Saunier A; Taverniers A; Pinet N; Josse T; Jeanmaire E; Emilie C; Schvoerer E; Hartard C
    J Med Virol; 2024 Aug; 96(8):e29870. PubMed ID: 39185639
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.